Two separate U.S. FDA surveillance inspections of Biocon’s API facilities in Bengaluru (Sites 1 & 2) concluded in September with a few observations. The Company has submitted individual Corrective and Preventive Action (CAPA) plans to the agency and is confident of addressing these expeditiously....
USD 800 million (INR 66,763 million) Senior Secured Notes (“Bonds”) The Largest High Yield Debut USD Bond Issuance from India in the Last 10 Years BENGALURU, Karnataka, India,October 3,2024 Summary Rationale: Strategic refinancing of debt will improve liquidity...
Bengaluru, Karnataka, India– March 28, 2023 Biocon Biologics Ltd(BBL), a subsidiary of Biocon Ltd, today announced that it has won the prestigious ‘Bioprocessing Excellence in South Asia’ Award at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2023 held in Singapore earlier this month...
Bengaluru, Karnataka, India, September 01, 2024 “This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg strengths, from the U....
Bengaluru, Karnataka, India, January 24, 2023 Biocon Foundation, the Corporate Social Responsibility (CSR) arm ofBiocon Limited,has been awarded theGold Awardin the‘Diseases Screening Initiative of the Year’category for its ‘Oral Cancer Screening Program’by theIndia Health...
Bengaluru, Karnataka, India, August 30, 2024 “This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval of its ANDA for Daptomycin for injection (500mg vial), from the U.S. Food and Drug Administration (US FDA). This product is ...
Bengaluru, Karnataka, India. April- 17th, 2024 Biocon Limited(BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceutical company, today announced the signing of an exclusive licensing and supply agreement with Biomm S.A., a specialty pharm...
Bengaluru, Karnataka, India: May 16, 2024: Biocon Limited(BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the fiscal fourth quarter and the financial year ended March 31, 2024. ...
Bengaluru, Karnataka, India: January 20, 2022: Biocon Ltd(BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the third quarter ended December 31, 2021. ...
Bengaluru, Karnataka, India, June 05, 2017: Biocon Ltd,Asia’s premier biopharmaceuticals company, announced today thatMs. Pratima Rao has been appointed as Mission Director & Head of Biocon Foundation*, the CSR arm of the Company. Prior to joining Foundation, Ms. Rao was heading the Departmen...